Detalhe da pesquisa
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother;
71(4): 865-874, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34462870
2.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Support Care Cancer;
30(3): 2455-2465, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34779921
3.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med;
19(1): 270, 2021 06 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34167578
4.
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib.
BJU Int;
128(2): 254-261, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33547860
5.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother;
69(11): 2209-2221, 2020 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32474768
6.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol;
234(6): 7708-7717, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30536609
7.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist;
24(6): e327-e337, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30796151
8.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med;
17(1): 376, 2019 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31730009
9.
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
J Transl Med;
17(1): 296, 2019 08 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31464635
10.
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients.
J Thromb Thrombolysis;
48(1): 125-133, 2019 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30919253
11.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
J Cell Physiol;
233(3): 2313-2323, 2018 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28710865
12.
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study.
Haematologica;
102(9): 1494-1501, 2017 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28550192
13.
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.
BMC Cancer;
17(1): 753, 2017 Nov 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29126389
14.
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Cochrane Database Syst Rev;
12: CD008500, 2016 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27906452
15.
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Ann Surg Oncol;
21(5): 1575-82, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24522992
16.
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
Ital J Dermatol Venerol;
158(6): 437-444, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38015482
17.
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Tumori;
109(2): 224-232, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35400269
18.
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Eur J Cancer;
187: 25-35, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37099946
19.
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
Nat Med;
29(3): 605-614, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36864254
20.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Clin Cancer Res;
29(14): 2714-2724, 2023 07 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37125965